Finding the right approaches to address how to translate novel science into high impact medicines is a critical mission of Translational Medicine at Regulus.  We start off with a keen understanding of a microRNA and its downstream pathways, always asking whether the mechanistic and phenotypic findings in preclinical research have relevance to human physiology and, more importantly, human diseases.  We then use this knowledge to determine which patients can best benefit from a particular microRNA-based therapeutic approach, and how we can design the appropriate clinical investigations to demonstrate its full potential in humans.  Once we have established an appropriate translational strategy, we leverage our expertise in microRNA research, oligonucleotide chemistry, and clinical development to quickly advance an efficacious, safe, and convenient therapeutic for diseases with high unmet need.

Regulus Partnered and Proprietary Pipeline
Multiple Programs Advancing to the Clinic

microRNA-based medicines have the potential to make significant impacts in multiple therapeutic areas with high unmet need, including oncology, immunology, fibrosis, and atherosclerosis